These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2789052)

  • 1. Characterization of the antitumor activity of a polyantigenic immunomodulator (PAI): I--Utilization of cimetidine and cyclosporine A.
    Ríos-Olivares E; Orraca ZM; Carrasco-Canales JA; Alvarado L; Marchand AM; Colón JI
    Bol Asoc Med P R; 1989 Jul; 81(7):246-53. PubMed ID: 2789052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the antitumor activity of a polyantigenic immunomodulator (PAI): II--Involvement of NK cells and adoptive immunotherapy.
    Orraca ZM; Ríos-Olivares E; Carrasco-Canales JA; Aquino E; Marchand AM; Colón JI
    Bol Asoc Med P R; 1989 Jul; 81(7):254-8. PubMed ID: 2775402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and quality of life in HIV-positive patients treated with a polyantigenic immunomodulator.
    Colón JI; Encarnación G; Ortiz Santini MR; Rodríguez Malavé MT; Santiago Delpín EA; Marchand AM
    P R Health Sci J; 1997 Mar; 16(1):9-14. PubMed ID: 9160397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in viral expression and cytokine profile induced by a polyantigenic immunomodulator in HIV-infected peripheral blood mononuclear cells.
    Ríos Z; Ríos EO; Garcia MI; De Leon C; Guzman LM; Rodriguez W; Romero D; Hunter R
    Cell Mol Biol (Noisy-le-grand); 1995; 41 Suppl 1():S93-101. PubMed ID: 8574153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of the suppressive activity of a biological response modifier on the proliferation of peripheral blood mononuclear cells and the reduction of HIV titer.
    Vila LM; Ríos-Olivares E; Vila S; Ríos Z; Rivera E; Robles R; Reyes JC; Castillo X
    Cell Mol Biol (Noisy-le-grand); 1997 Nov; 43(7):981-8. PubMed ID: 9449530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae).
    Da Silva SL; Chaar Jda S; Yano T
    Eur J Pharmacol; 2009 Apr; 608(1-3):76-83. PubMed ID: 19222998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP; Schlom J; Kantor JA; Greiner JW
    Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
    Cao X; Wang Q; Ju DW; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of the nucleic acids from the ascitic fluid of Ehrlich's tumor on its transplantability].
    Belokhvostov AS; Grikurova NK
    Vopr Onkol; 1981; 27(12):56-9. PubMed ID: 7324403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
    Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
    Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine profile of Ehrlich ascites tumor treated with Bothrops jararaca venom.
    da Silva RJ; da Silva MG; Vilela LC; Fecchio D
    Mediators Inflamm; 2002 Aug; 11(4):197-201. PubMed ID: 12396470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of interleukin-12 against murine bladder cancer.
    Eto M; Harada M; Tamada K; Tokuda N; Koikawa Y; Nakamura M; Nomoto K; Naito S
    J Urol; 2000 May; 163(5):1549-52. PubMed ID: 10751886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antitumor activity of doxorubicin in the treatment of hemocytoblastosis La and various ascites tumors in mice].
    Ul'ianova LA; Tarasova VE; Bazhanov VS; Iudina OI; Gol'dberg LE
    Antibiotiki; 1984 Nov; 29(11):861-6. PubMed ID: 6524889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of antitumor effects of paclitaxel (taxol) in combination with red ginseng acidic polysaccharide (RGAP).
    Shin HJ; Kim YS; Kwak YS; Song YB; Kim YS; Park JD
    Planta Med; 2004 Nov; 70(11):1033-8. PubMed ID: 15549658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
    You J; Wang CL; Hao XS
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
    Spiess PJ; Yang JC; Rosenberg SA
    J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.